Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

The news came as Roche recorded a 10% increase in first-quarter revenues to CHF 16.4 billion ($17.2 billion), on strong US demand for rapid COVID-19 antigen tests, as well as the performances of ...

If you're not looking to trade, then Boost Infinity's latest promotion is well worth considering since it allows you to throw in a shiny new iPhone 16 Pro alongside an unlimited plan for as little ...

If you watched this year's iPhone launch event, you could've been forgiven for thinking that the iPhone XS is the most underwhelming 'S' upgrade in the iPhone's history. Apple spent surprisingly ...

Merck's injected version of its blockbuster cancer drug Keytruda could face a potential patent challenge from biotech Halozyme Therapeutics , the Wall Street Journal reported on Wednesday, citing ...

App Store and the Apple logo are trademarks of Apple Inc. Google Play and the Google Play logo are trademarks of Google LLC. © carsales.com.au Pty Ltd 1999-2025 In ...